Related Experiment Videos
Gd HP-DO3A--experimental evaluation in brain and renal MR
V M Runge1, D Y Gelblum, S Jacobson
1Department of Radiology, University of Kentucky Medical Center, Lexington 40536.
Magnetic Resonance Imaging
|January 1, 1991
Summary
Gadolinium hydroxyethoxyethyl diethylenetriamine triacetic acid (GD HP-DO3A) shows comparable brain and kidney enhancement to Gd-DTPA in rats. This new MRI contrast agent may allow for higher clinical doses without adverse effects.
Area of Science:
- Radiology
- Medical Imaging
- Pharmacology
Background:
- Gadolinium-based contrast agents (GBCAs) are crucial for Magnetic Resonance Imaging (MRI).
- GD HP-DO3A is a novel nonionic intravenous GBCA undergoing clinical trials.
- Evaluating its efficacy and safety is essential for clinical application.
Purpose of the Study:
- To assess the imaging characteristics of GD HP-DO3A in a rat model.
- To compare its enhancement patterns in brain and kidney with existing agents like Gd-DTPA.
- To determine the safety profile at potentially higher clinical doses.
Main Methods:
- Administered GD HP-DO3A intravenously at 0.25 mmol/kg in rats with brain gliosarcoma.
- Quantitated renal enhancement at 0.05 and 0.25 mmol/kg doses.
- Analyzed enhancement in brain tumors, meninges, and renal cortex/medulla over time.
Main Results:
- Significant enhancement of brain gliosarcoma (58 +/- 19%) and meningeal neoplasia (69 +/- 26%) was observed.
- Renal cortex and medulla enhancement plateaued between 9-23 min at 0.25 mmol/kg.
- Renal medulla enhancement peaked at 2 min at 0.05 mmol/kg.
- Brain and kidney enhancement were comparable to Gd-DTPA at equivalent doses.
Conclusions:
- GD HP-DO3A demonstrates effective contrast enhancement in brain and renal imaging in rats.
- Its performance is similar to Gd-DTPA, suggesting potential clinical utility.
- Initial trials indicate GD HP-DO3A may tolerate higher doses (up to 0.3 mmol/kg) than Gd-DTPA without adverse effects.